Asia Deal Watch: Eisai Advances Portfolio Focus With Divestiture Of Two Products To DKSH
Plus deals involving Dong-A/Polifarma, Intas/Syna, Kissei/Synmosa, Ono/Memo, Takeda/Shionogi, Fosun/Lilly and JW Therapeutics/2seventy bio.
You may also be interested in...
Lupin has acquired all US market rights to Sunovion’s Brovana and Xopenex HFA branded inhalation products for $75m, strengthening its presence in the US respiratory market.
Sumitovant, a Sumitomo subsidiary, will pay $27 per share for the 48% of Myovant shares it does not already own, for a deal value of $1.7bn, up from a $22.75-per-share bid in early October.
The formal split between the companies had been in the works since January, with 2seventy set to take over oncology operations while bluebird focuses on gene therapies.